Research programme: Id protein modulators - AngioGenex

Drug Profile

Research programme: Id protein modulators - AngioGenex

Alternative Names: AGX 1053; AGX 51; AGX 8

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer AngioGenex
  • Class Antisense DNA; Peptides; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Inhibitor of differentiation protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Eye disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in USA
  • 11 Dec 2007 Pharmacodynamics data from a preclinical study released by AngioGenex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top